Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | GPR35 | Q9HC97 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dinitro Cresol SCHEMBL1716451 | 0.83 | GPR35 (0.93) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL8873755 | 0.83 | GPR35 (1.00) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL20734 | 0.83 | GPR35 (1.00) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL29430312 | 0.83 | GPR35 (1.00) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL7554038 | 0.82 | ALDH1A1 (0.68) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL2549698 | 0.82 | GPR35 (0.89) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL7108490 | 0.82 | GPR35 (0.96) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL1260257 | 0.82 | GPR35 (0.96) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL9640831 | 0.82 | GPR35 (0.96) | ALDH1A1GPR35MAPTKDM4EKMT2A | |
| Dinitro Cresol SCHEMBL11029120 | 0.82 | GPR35 (0.96) | ALDH1A1GPR35MAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444807-B1 | MONO- AND DINITROPYRAZOLE HAPTEN CONJUGATES | VENTANA MED SYST INC (US) | 2014-06-11 | — | — | EP | claimed |
| EP-2444806-B1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MED SYST INC (US) | 2014-05-28 | — | — | EP | claimed |
| EP-2444806-A2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | Ventana Medical Systems, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| EP-2444807-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| EP-2078197-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2008063378-A9 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2008-07-31 | — | — | WO | claimed |
| WO-2008063378-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3564674-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3276349-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9719986-B2 | Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-3029461-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100184087-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2078197-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008063378-A9 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008063378-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | ALDH1A1 2096/4885GPR35 311/4885MAPT 3454/4885 |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | CRBN, AHR, RORB | ALDH1A1 2734/4885GPR35 217/4885MAPT 2927/4885 |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, GABBR1, SHBG | ALDH1A1 3347/4885GPR35 310/4885MAPT 2915/4885 |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, AHR, RORB | ALDH1A1 2734/4885GPR35 217/4885MAPT 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.